About Nociceptin receptor
Nociceptin receptor (OPRL1) is a protein
from Homo sapiens identified by UniProt accession
P41146, 370 residues long.
MolForge cross-references it against 0 known binders and
158 disease associations.
Target properties
| Protein name | Nociceptin receptor |
| UniProt accession | P41146 |
| Gene | OPRL1 |
| Organism | Homo sapiens |
| Length | 370 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (4)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (158)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.40
- triglyceride measurement · score 0.31
- BMI-adjusted waist-hip ratio · score 0.30
- pain · score 0.28
- BMI-adjusted waist circumference · score 0.27
- testosterone measurement · score 0.27
- high density lipoprotein cholesterol measurement · score 0.27
- mean corpuscular volume · score 0.26
- glioblastoma multiforme · score 0.26
- cardiovascular disease · score 0.26
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P41146-F1 | alphafold | PREDICTED | 82.30 | — |
Amino-acid sequence (370 residues)
MEPLFPAPFW EVIYGSHLQG NLSLLSPNHS LLPPHLLLNA SHGAFLPLGL KVTIVGLYLA VCVGGLLGNC LVMYVILRHT KMKTATNIYI FNLALADTLV LLTLPFQGTD ILLGFWPFGN ALCKTVIAID YYNMFTSTFT LTAMSVDRYV AICHPIRALD VRTSSKAQAV NVAIWALASV VGVPVAIMGS AQVEDEEIEC LVEIPTPQDY WGPVFAICIF LFSFIVPVLV ISVCYSLMIR RLRGVRLLSG SREKDRNLRR ITRLVLVVVA VFVGCWTPVQ VFVLAQGLGV QPSSETAVAI LRFCTALGYV NSCLNPILYA FLDENFKACF RKFCCASALR RDVQVSDRVR SIAKDVALAC KTSETVPRPA
Explore Nociceptin receptor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets